摘要
目的:观察国产抗肿瘤血管生成剂重组人血管内皮抑制素(恩度)与化疗药物联合治疗晚期胃癌的有效性和安全性。方法:2007年1月～2009年1月,9例晚期胃癌患者接受恩度联合常规化疗药物治疗。恩度7.5mg/m2(15mg/d),加入生理盐水500ml内静滴,连用14天为1疗程。同时,有4例患者采用FOLFOX4方案,4例患者采用喜树碱类为主的方案,1例患者采用紫杉醇为主的方案化疗。分别按照RECIST标准和NCI-CTC 3.0评价疗效和毒性。结果:9例中8例可评价疗效。获3例PR,4例SD,1例PD。总有效率37.5%,疾病控制率87.5%。4例一线治疗者获PR、SD各2例;2例二线治疗者获PR、SD各1例;2例四线治疗者获SD、PD各1例。疾病进展时间(TTP)为2～14个月。9例患者均可评价毒性,主要毒副反应为粒细胞减少、恶心呕吐、乏力和虚弱,考虑主要与化疗相关;未见明显心血管系统毒性和出血情况。结论:初步观察恩度联合化疗药物治疗晚期胃癌疗效明显,不增加化疗毒性,安全性高,值得进一步积累病例和积极开展多中心临床协作研究。
Objective：To observe the efficacy and toxicity of rh-endostatin（endostar） combined with chemotherapy for advanced gastric cancer.Methods：Between January 2007 and January 2009,9 patients with advanced gastric cancer were treated with endostar combined with routine chemotherapy.Endostar 15mg/d administered intravenously on day 1 to day 14,including 4 patients with concurrent FOLFOX4 regimen,4 patients with concurrent camptothecin plus 5-fluorouracil,1 patient with concurrent taxane.The efficacy and toxicity were evaluated according RECIST and NCI-CTC 3.0 criteria.Results：The 9 patients may be evaluated the toxicities and 8 patients were evaluated the efficacy.The response rate was 37.5%,and the disease control rate was 87.5%（PR 3,SD 4 and PD 1）.Among the patients who previously untreated with chemotherapy,2 patients got PR,2 patients SD.Among the patients with second-line therapy,1 patient got PR,1 patient SD.Two patients achieved fourth-line therapy,1 patient SD,1 patient PD.Time to progression（TTP） was 2-14 months.The common toxicities were hematological toxicity,vomiting and fatigue,which were considered as side effects of chemotherapy.There wasn＇t any adverse events of cardiovascular system and hemorrhage.Conclusion：Endostar combined with chemotherapy is effective for metastatic advanced gastric cancer.The addition of endostar weren＇t increasing the toxicities of chemotherapy.It is reasonable that the further multi-center clinical study is needed.
出处
《临床肿瘤学杂志》
CAS
2009年第4期327-331,共5页
Chinese Clinical Oncology
基金
南京军区医学创新重点课题资助项目(2007)
